Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491534 | SCV000580054 | pathogenic | Hereditary cancer-predisposing syndrome | 2015-03-09 | criteria provided, single submitter | clinical testing | The c.179delA pathogenic mutation, located in coding exon 3 of the PTEN gene, results from a deletion of one nucleotide at position 179, causing a translational frameshift with a predicted alternate stop codon. This mutation has previously been reported as de novo in an individual diagnosed with Lhermitte-Duclos disease (LDD), and was subsequently detected in his son (Delatycki MB et al. J Med Genet. 2003 Aug;40(8):e92; Pilarski R and Eng C. J Med Genet. 2004 May;41(5):323-6). In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Human Genome Sequencing Center Clinical Lab, |
RCV001258102 | SCV001434948 | pathogenic | PTEN hamartoma tumor syndromes | 2019-02-18 | criteria provided, single submitter | clinical testing | The c.179delA (p.Lys60Serfs*39) variant in the PTEN gene is predicted to introduce a premature translation termination codon, which is predicted to result in nonsense-mediated mRNA decay. This variant is absent from large databases of genetic variation in the general population. This variant has been reported de novo in one family affected with Lhermitte-Duclos disease (PMID 12920084). Therefore, c.179delA (p.Lys60Serfs*39) variant in the PTEN gene is classified as pathogenic. |